Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRIGrowth Rate was 30.90% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 39.10% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 65.30% per year.
During the past 13 years, BioRestorative Therapies's highest 3-Year average EPS without NRI Growth Rate was 89.60% per year. The lowest was 21.20% per year. And the median was 34.00% per year.
BioRestorative Therapies (FRA:9OF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
BioRestorative Therapies Earnings per Share (Diluted) Related Terms
BioRestorative Therapies Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for BioRestorative Therapies's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies Earnings per Share (Diluted) Chart
FRA:9OF vs LIMN, BOLT, TRAW: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, BioRestorative Therapies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's PE Ratio distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's PE Ratio falls into.
BioRestorative Therapies Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
BioRestorative Therapies's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of €-0.92 mean?
BioRestorative Therapies (FRA:9OF) has a Earnings per Share (Diluted) of €-0.92 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on BioRestorative Therapies and its competitors. According to the industry distribution chart, BioRestorative Therapies ranks #379 out of 1161 companies in the Biotechnology industry, placing it in the top 32.6%.
Is BioRestorative Therapies' Earnings per Share (Diluted) too high?
BioRestorative Therapies' current Earnings per Share (Diluted) is €-0.92. Based on the distribution chart, BioRestorative Therapies ranks #379 out of 1161 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioRestorative Therapies has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Earnings per Share (Diluted) compare to LIMN and BOLT?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #379 out of 1161 companies for Earnings per Share (Diluted). This puts BioRestorative Therapies in the upper half of its industry. The industry median Earnings per Share (Diluted) is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on BioRestorative Therapies and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current Earnings per Share (Diluted) is €-0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.29, compared to a current price of €0.19 — trading 85.2% below its estimated fair value. The current Earnings per Share (Diluted) is €-0.92. BioRestorative Therapies' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current Earnings per Share (Diluted) is €-0.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.19 is trading 85.2% below its estimated GF Value™ of €1.29.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for FRA:9OF:
Earnings per Share (Diluted): €-0.92
GF Value™: €1.29 vs. price of €0.19 (85.2% below fair value)
No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
59GF Score
Get the complete analysis for FRA:9OF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9OF has been successfully added to your 
